Reid Physician Associates

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease6 trials
• Heart failure5 trials
• Stroke3 trials
• Obesity2 trials
• Type 2 diabetes2 trials
• Atrial fibrillation1 trial
• Chronic kidney disease1 trial
• Familial hypercholesterolaemia1 trial
• High blood pressure1 trial
• Peripheral artery disease1 trial

Phase

• Phase 37 trials
• Phase 22 trials
• Phase 42 trials

Status

• Recruiting7 trials
• Active, not recruiting3 trials
• Completed1 trial

Lead sponsor

• Amgen3 trials
• Boehringer Ingelheim2 trials
• Cytokinetics1 trial
• Duke University1 trial
• Eli Lilly and Company1 trial
• and 3 more

Running trials

• Recruiting

  Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

  NCT07175428· Phase 2· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

  NCT06909565· Phase 4· Duke University· Source

  Contact: Kristi McGuire

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

  NCT06991257· Phase 2· Pfizer· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

  Contact: Cytokinetics MD

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

  NCT05284747· Phase 4· Amgen· Source

• Active, not recruiting

  Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

  NCT05360446· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure3 recruiting
• Coronary artery disease2 recruiting
• Atrial fibrillation1 recruiting
• Familial hypercholesterolaemia1 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source